These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 15074774)
1. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine]. Belardinelli R Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774 [TBL] [Abstract][Full Text] [Related]
2. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Belardinelli R Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102 [TBL] [Abstract][Full Text] [Related]
3. Role of trimetazidine in management of ischemic cardiomyopathy. Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202 [TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Lopaschuk GD; Barr R; Thomas PD; Dyck JR Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392 [TBL] [Abstract][Full Text] [Related]
5. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390 [TBL] [Abstract][Full Text] [Related]
6. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409 [TBL] [Abstract][Full Text] [Related]
7. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070 [TBL] [Abstract][Full Text] [Related]
8. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696 [TBL] [Abstract][Full Text] [Related]
9. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Belardinelli R; Lacalaprice F; Faccenda E; Volpe L Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405 [TBL] [Abstract][Full Text] [Related]
10. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947 [TBL] [Abstract][Full Text] [Related]
11. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391 [TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of a metabolic approach in the management of coronary patients. Marzilli M Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V25-30. PubMed ID: 11206100 [TBL] [Abstract][Full Text] [Related]
13. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Kantor PF; Lucien A; Kozak R; Lopaschuk GD Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420 [TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease. Belardinelli R; Lacalaprice F; Faccenda E; Volpe L Am J Cardiol; 2006 Sep; 98(5A):25J-33J. PubMed ID: 16931203 [TBL] [Abstract][Full Text] [Related]
15. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466 [TBL] [Abstract][Full Text] [Related]
16. ["Persistent" angina: rationale for a metabolic approach]. Marzilli M Ital Heart J; 2004 Mar; 5 Suppl 2():37S-41S. PubMed ID: 15074776 [TBL] [Abstract][Full Text] [Related]
17. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Monti LD; Setola E; Fragasso G; Camisasca RP; Lucotti P; Galluccio E; Origgi A; Margonato A; Piatti P Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E54-E59. PubMed ID: 16174656 [TBL] [Abstract][Full Text] [Related]
18. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Rosano GM; Vitale C; Fragasso G Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201 [TBL] [Abstract][Full Text] [Related]
19. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Wenmeng W; Qizhu T Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648 [TBL] [Abstract][Full Text] [Related]
20. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Belardinelli R; Purcaro A Eur Heart J; 2001 Dec; 22(23):2164-70. PubMed ID: 11913478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]